Individuals with treatment-resistant depression do not achieve and sustain remission after multiple pharmacotherapies, with an unknown impact on employment. This study investigates the expenditures of TRD from a private-payer perspective in Canada.
Beena Kuriakose, PharmD
Advertisement
Articles by Beena Kuriakose, PharmD
Advertisement
Latest Updated Articles
- Private-payer Costs for Employees with Treatment-resistant Depression
Published: August 18th 2016 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
MFN, DTC, and the Policy Pressure Cooker: Reshaping the US Drug Market
2
Oral Semaglutide Shows Promise for Weight Loss and Cardiometabolic Health
3
A Review of Antibody-Drug Conjugates for the Treatment of Urothelial Carcinoma: The Rise of Enfortumab Vedotin
4
FDA Approves Lumateperone With Antidepressant Use for Major Depressive Disorder
5
